• Removal of inciting agent induces improvement.
• Typical biopsy of involved organs.
Minor criteria are:
• The appearance of autoantibodies or antibodies directed at the suspected adjuvants.
• Other clinical manifestations such as irritable bowel syndrome.
• Specific human leukocyte antigen (HLA).
• Evolvement of an autoimmune disease.
These criteria are highly specific and sensitive, but could change based on further analysis, he said, noting that the "amassed data" regarding conditions that can be considered part of ASIA "may enable us a spacious view of the immune responses to environmental adjuvants, as well as better definition and diagnosis of these conditions. Moreover, unraveling the pathogenesis of this newly defined syndrome may facilitate the search for preventive and therapeutic inventions," he wrote.
Dr. Shoenfeld reported having no disclosures.